Text Size

Pre-Admission Hyperglycemia and Its Effect on Morbidity and Mortality

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2009 by North Shore Long Island Jewish Health System.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
North Shore Long Island Jewish Health System
ClinicalTrials.gov Identifier:
NCT00871832
First received: March 26, 2009
Last updated: March 27, 2009
Last verified: March 2009
History of Changes
  Purpose

It is currently standard of care in many Medical and Surgical ICU's to institute a nurse driven insulin protocol in maintaining tight glucose control in the critical patient. Many articles have been written to address this topic. However, there is no current data regarding the use of glycohemoglobin as a marker of risk of morbidity and mortality. In our study we would like to determine whether or not the HbA1C could be used as a marker of morbidity and mortality. The HbA1C is a simple blood test that may be added on to any CBC collection tube; a blood sample that critical patients have drawn up to several times a day. The investigators would analyze this information in respect to the rest of the clinical data collected regarding the patient's illness.


Condition
Hyperglycemia

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: To Evaluate if Pre-Admission Hyperglycemia Measured by Glycosylated Hemoglobin Level Affects the Morbidity and Mortality of Patients in a Mixed Medical and Surgical Intensive Care Unit

Resource links provided by NLM:

MedlinePlus related topics: Hyperglycemia
U.S. FDA Resources

Further study details as provided by North Shore Long Island Jewish Health System:

Estimated Enrollment: 1200
Study Start Date: May 2007
Estimated Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

All patients admitted to the medical and surgical ICU, and CCU that are 18 year's or older and speech English that give consent.

Criteria

Inclusion Criteria:

  • All patients admitted to the medical and surgical ICU, and CCU that are 18 year's or older and speech English that give consent.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00871832

Locations
United States, New York
Staten Island University Hospital
Staten Island, New York, United States, 10305
Sponsors and Collaborators
Staten Island University Hospital
  More Information

No publications provided

Responsible Party: Mario Castellanos, MD, Staten Island University Hospital
ClinicalTrials.gov Identifier: NCT00871832     History of Changes
Other Study ID Numbers: 07-020
Study First Received: March 26, 2009
Last Updated: March 27, 2009
Health Authority: United States: Institutional Review Board

Keywords provided by North Shore Long Island Jewish Health System:
hyperglycemia
HgA1c
mortality

Additional relevant MeSH terms:
Hyperglycemia
Glucose Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on May 16, 2013